Assessment of the usefulness of anti-Wb123 antibody for post-elimination surveillance of lymphatic filariasis
- PMID: 33407812
- PMCID: PMC7789272
- DOI: 10.1186/s13071-020-04535-y
Assessment of the usefulness of anti-Wb123 antibody for post-elimination surveillance of lymphatic filariasis
Abstract
Background: The World Health Organization has targeted lymphatic filariasis (LF) for elimination as a public health problem and recommends, among other measures, post-elimination surveillance of LF. The identification of sensitive and specific surveillance tools is therefore a research priority. The Wuchereria bancrofti-specific antigen Wb123-based enzyme-linked immunosorbent assay (Wb123 ELISA) detects antibodies to the recombinant Wb123 antigen of W. bancrofti and may be useful as a surveillance tool for LF. Six years after stopping mass drug administration to eliminate LF and recording successful results on two post-treatment transmission assessment surveys, a study was conducted in Togo aimed at helping to identify the role of the Wb123 ELISA in post-validation surveillance of LF.
Methods: This was a cross-sectional study in eight previously LF-endemic districts and one non-endemic district in Togo. In each sub-district of these nine districts, two schools were selected and 15 children aged 6 to 9 years old at each school provided finger-stick blood for testing for antibodies to Wb123 using the Filaria DetectTM IgG4 ELISA kit® (InBios, International, Inc., Seattle, WA, USA).
Results: A total of 2654 children aged 6 to 9 years old were tested in 134 schools in the nine districts. Overall, 4.7% (126/2654) children tested positive for antibodies to the Wb123 antigen of W. bancrofti. The prevalence of Wb123 antibodies varied across the eight previously endemic LF districts, from 1.56 to 6.62%. The highest prevalence, 6.99%, was found in the non-endemic district, but this was not significantly different from the average of all the LF districts (4.49%, P = 0.062).
Conclusions: The Wb123 ELISA was positive in 4.7% of Togolese school-age children who were almost certainly unexposed to LF. This apparent lack of specificity in the Togo context makes it difficult to establish a seroprevalence threshold that could serve to signal LF resurgence in the country, precluding the use of this test for post-validation surveillance in Togo. There remains a need to develop a useful and reliable test for post-elimination surveillance for LF in humans.
Keywords: Lymphatic filariasis; Post-validation surveillance; Surveillance; Togo; Wb123.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
References
-
- World Health Organization (WHO). Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021–2030. Geneva: World Health Organization. 2020. https://apps.who.int/iris/handle/10665/332094. Accessed 8 May 2020.
-
- World Health Organization (WHO). Lymphatic filariasis epidemiology. Geneva: World Health Organization. 2018. http://www.who.int/lymphatic_filariasis/epidemiology/en. Accessed 8 May 2020.
-
- Sodahlon YK, Dorkenoo AM, Morgah K, Nabiliou K, Agbo K, Miller R, et al. A success story: Togo is moving toward becoming the first sub-Saharan African nation to eliminate lymphatic filariasis through mass drug administration and countrywide morbidity alleviation. PLoS Negl Trop Dis. 2013;7:e2080. doi: 10.1371/journal.pntd.0002080. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources